Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COPD Exacerbation Clear all
Completed No phase listed Observational

T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281229
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional Results available

Integrating Care After Exacerbation of COPD

NCT02021955
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
guideline treatment recommendations
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boise, Idaho • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 7:41 AM EDT
Active, not recruiting Not applicable Interventional

Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke

NCT07118189
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
N95 masks and indoor air cleaner
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Effects of Nasal High-flow Oxygen in Patients With an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03214458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Nasal high flow
Device
Lead sponsor
Temple University
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02164513
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
10,355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
269
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 20, 2026, 7:41 AM EDT
Terminated No phase listed Observational

COPD Exacerbation Blood and Urine Biomarkers Study

NCT03823443
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Acute Exacerbation Copd, Alpha-1 Anti-trypsin Deficiency
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 20, 2026, 7:41 AM EDT
Completed No phase listed Observational Results available

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

NCT05169424
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
9,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV

NCT01892566
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 100 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

NCT00297102
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Fullerton, California • Los Angeles, California • Palmdale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Active, not recruiting Phase 2 Interventional

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT06175065
View directory record Official record
Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
St. Petersburg, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628
View directory record Official record
Conditions
COPD
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02155660
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 20, 2026, 7:41 AM EDT
Completed No phase listed Observational

Diagnosing Respiratory Disease in Children Using Cough Sounds 2

NCT03392363
View directory record Official record
Conditions
Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup, Reactive Airway Disease, Upper Respiratory Disease, Viral Lower Respiratory Tract Infections, Lower Respiratory Disease
Interventions
Recordings of Infants and Children's Cough Sounds
Device
Lead sponsor
ResApp Health Limited
Industry
Eligibility
29 Days to 12 Years
Enrollment
1,470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia

NCT05452226
View directory record Official record
Conditions
Community-acquired Pneumonia, COPD Exacerbation Acute
Interventions
neuromuscular electrical stimulation (NMES)
Device
Lead sponsor
University of Vermont
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Loop Band Validation Study

NCT03240926
View directory record Official record
Conditions
COPD
Interventions
Loop Band
Device
Lead sponsor
Spry Health
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting Phase 4 Interventional

This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

NCT07587658
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mullica Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional Results available

The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD

NCT02099799
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis
Interventions
Pedometer and Website
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 20, 2026, 7:41 AM EDT
Withdrawn Not applicable Interventional

Probiotic Use in Patients With Prior COPD Exacerbation

NCT02185092
View directory record Official record
Conditions
COPD, Obstructive Lung Disease
Interventions
Lactobacillus GG, Sugar pill
Dietary Supplement · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 20, 2026, 7:41 AM EDT
Not listed Not applicable Interventional

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

NCT06304207
View directory record Official record
Conditions
Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD, Chronic Lung Disease, Pulmonary Fibrosis, Interstitial Lung Disease, Bronchiectasis, Chronic Asthma, Chronic Asthmatic Bronchitis
Interventions
Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
Combination Product
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 4 Interventional Results available

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

NCT00181207
View directory record Official record
Conditions
COPD, Chronic Bronchitis, Emphysema
Interventions
pneumatic vest, placebo pneumatic vest
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 20, 2026, 7:41 AM EDT
Completed No phase listed Observational

Healthy At Home Pilot

NCT06000696
View directory record Official record
Conditions
COPD, COPD Exacerbation, Emphysema or COPD
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 20, 2026, 7:41 AM EDT
Enrolling by invitation No phase listed Observational

Study on Home Obstructive Respiratory Exacerbations

NCT06544928
View directory record Official record
Conditions
COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, COPD Exacerbation Acute, COPD
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

NCT04353661
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Azithromycin, HP xenon (¹²⁹XE)
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 20, 2026, 7:41 AM EDT